

2008 Accomplishments and Highlights

- Received U.S. approval for TREANDA[®] (bendamustine HCl) for Injection for the treatment of chronic lymphocytic leukemia and a second approval for the treatment of patients with refractory indolent non-Hodgkin's lymphoma. TREANDA was one of only 21 New Chemical Entities approved by the FDA in 2008, and one of 2008's 12 Major Advances in Cancer Treatment and Prevention named by the American Society of Clinical Oncology.
- Generated record sales of \$1.943 billion in 2008, exceeding our sales guidance for the year
- Exceeded \$1 billion in 2008 sales for our central nervous system franchise, anchored by flagship product PROVIGIL[®] (modafinil) Tablets [C-IV]
- Patent issued for AMRIX[®] (Cyclobenzaprine Hydrochloride Extended-Release Capsules) that expires in 2025
- Added to the S&P 500 Index, a remarkable accomplishment for a company which launched its first product, PROVIGIL, only ten years ago; and named to the Forbes 400 listing of the Best Big Companies in America.
- Announced option agreement for exclusive, worldwide license to LUPUZOR[™] for the treatment of patients with systemic lupus erythematosus; subsequently triggered option in January 2009
- Received European Commission approval for EFFENTORA
- Filed an IMPD, the European equivalent of an IND, for our PARP inhibitor in oncology, CEP-9722.